concept

POR

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about POR: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

99Connections

30Hypotheses

0Analyses

50Outgoing

41Incoming

12Experiments

0Debates

No summary available yet.

View on Wiki →

No AI portrait yet

💡 Concept Info

Name	POR
Key Genes/Proteins	ABCB1, ACE, ACSL4, ALZHEIMER, ALZHEIMER'S DISEASE, APOE
Related Diseases	Als, ALS, Alzheimer
Related Pathways	Autophagy, Complement

Wiki Pages (1)

Knowledge base pages for this entity

RIPOR1 Protein (Rho Family Interacting Protein 1)

protein · 1063 words

→

Pathway Diagram

graph TD
    POR["POR"]
    POR -->|"activates"| Als["Als"]
    POR -->|"activates"| Ms["Ms"]
    POR -->|"activates"| ALS["ALS"]
    POR -->|"target for"| Parkinson["Parkinson"]
    POR -->|"target for"| Dementia["Dementia"]
    LPCAT3["LPCAT3"] -->|"regulates"| POR
    ACSL4["ACSL4"] -->|"regulates"| POR
    NOX["NOX"] -->|"activates"| POR
    SPHK1["SPHK1"] -->|"interacts"| POR
    SOAT1["SOAT1"] -->|"interacts"| POR
    AUTOPHAGY["AUTOPHAGY"] -->|"interacts"| POR

Outgoing (58)

Target	Relation	Type	Str
Als	regulates	disease	0.65
Als	transports	disease	0.65
Alzheimer	associated_with	disease	0.65
Als	associated_with	disease	0.65
Dementia	therapeutic_target	disease	0.65
Parkinson	therapeutic_target	disease	0.65
Ms	activates	disease	0.65
ALS	activates	disease	0.65
Vascular Dementia	associated_with	disease	0.65
Dementia	transports	disease	0.65
ALS	associated_with	disease	0.65
Frontotemporal Dementia	associated_with	disease	0.65
Als	activates	disease	0.65
LIPID_PEROXIDATION	activates	phenotype	0.64
MLKL	interacts_with	gene	0.60
AUTOPHAGY	interacts_with	gene	0.60
ROS	activates	gene	0.60
CYP3A5	therapeutic_target	gene	0.60
ALZHEIMER	associated_with	gene	0.60
CHAT	therapeutic_target	gene	0.60
CYP3A4	therapeutic_target	gene	0.60
APOE	therapeutic_target	gene	0.60
DEMENTIA	therapeutic_target	gene	0.60
CYP2D6	therapeutic_target	gene	0.60
ABCB1	therapeutic_target	gene	0.60
ACE	therapeutic_target	gene	0.60
NR1I2	therapeutic_target	gene	0.60
CHRNA7	therapeutic_target	gene	0.60
PPAR	therapeutic_target	gene	0.60
Neuron	therapeutic_target	cell_type	0.60
Ras	activates	protein	0.60
Ras	therapeutic_target	protein	0.60
ferroptosis	participates_in	pathway	0.60
PPAR	regulates	gene	0.60
SLC22A1	regulates	gene	0.60
ferroptosis	regulates	process	0.60
PARKINSON	therapeutic_target	gene	0.60
PARKINSON'S DISEASE	therapeutic_target	gene	0.60
Complement	associated_with	pathway	0.60
LPCAT3	interacts_with	gene	0.60
RIPK1	interacts_with	gene	0.60
SOAT1	interacts_with	gene	0.60
BCHE	transports	gene	0.60
CYP3A5	transports	gene	0.60
NR1I2	transports	gene	0.60
CHRNA7	transports	gene	0.60
ALZHEIMER'S DISEASE	associated_with	gene	0.60
CYP2D6	transports	gene	0.60
SLC22A1	transports	gene	0.60
CYP3A4	transports	gene	0.60

Incoming (41)

Source	Relation	Type	Str
SPHK1	interacts_with	gene	0.60
LPCAT3	interacts_with	gene	0.60
SOAT1	interacts_with	gene	0.60
AUTOPHAGY	interacts_with	gene	0.60
RIPK1	interacts_with	gene	0.60
MLKL	interacts_with	gene	0.60
GPX4	interacts_with	gene	0.60
ROS	activates	gene	0.60
APOE	interacts_with	gene	0.60
NOX	regulates	gene	0.60
ABCB1	regulates	gene	0.60
ACE	regulates	gene	0.60
CHAT	regulates	gene	0.60
CHRNA7	regulates	gene	0.60
CYP2D6	regulates	gene	0.60
CYP3A4	regulates	gene	0.60
CYP3A5	regulates	gene	0.60
NR1I2	regulates	gene	0.60
APOE	therapeutic_target	gene	0.60
CHRNA7	therapeutic_target	gene	0.60
DEMENTIA	therapeutic_target	gene	0.60
NR1I2	therapeutic_target	gene	0.60
PPAR	therapeutic_target	gene	0.60
ABCB1	therapeutic_target	gene	0.60
CHAT	therapeutic_target	gene	0.60
CYP2D6	therapeutic_target	gene	0.60
CYP2C19	regulates	gene	0.60
FERROPTOSIS	regulates	gene	0.60
LPCAT3	regulates	gene	0.60
ACSL4	regulates	gene	0.60
NOX	activates	gene	0.60
PPAR	transports	gene	0.60
DEMENTIA	transports	gene	0.60
GENES	transports	gene	0.60
APOE	transports	gene	0.60
ABCB1	transports	gene	0.60
CHAT	transports	gene	0.60
ALZHEIMER	associated_with	gene	0.60
ACE	transports	gene	0.60
CYP3A5	therapeutic_target	gene	0.60
CYP3A4	therapeutic_target	gene	0.60

Targeting Hypotheses (30)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
Plasma NfL Elevation Secondary to BBB-Associated Transport D	0.940	-	What blood-brain barrier permeability ch
Optimized Temporal Window for Metabolic Boosting Therapy Det	0.887	neurodegeneration	How do different microglial subtypes (DA
hnRNP A2/B1 Staufen2-Mediated Axonal RNA Granule Transport F	0.851	als	-
GLE1-Mediated mRNA Export Defect Creates Translation-Compete	0.823	als	-
SASP-Driven Aquaporin-4 Dysregulation	0.782	neurodegeneration	Senolytic therapy for age-related neurod

Selective LXRβ agonists restore ABCA1/ABCG1 expression and A	0.763	neuroscience	APOE4-driven lipid metabolism dysregulat
N-acetylcysteine (NAC) / System Xc⁻ - Mediated GSH Support f	0.760	neurodegeneration	Can ferroptosis inhibitors prevent BBB d
APOE4 astrocytes exhibit impaired cholesterol efflux via ABC	0.758	neuroscience	APOE4-driven lipid metabolism dysregulat
Temporal SPP1 Inhibition During Critical Windows	0.752	neuroinflammation	What molecular mechanisms mediate SPP1-i
APOE4-driven lysosome-to-ER cholesterol transport failure re	0.741	molecular-biology	Does APOE4's reduced lipid-binding direc
C9orf72 Hexanucleotide Repeat Dipeptide Repeat Proteins Inhi	0.738	neurodegeneration	Legacy Pre-Pipeline Hypothesis Import
Aquaporin-4 Polarization Rescue	0.732	neurodegeneration	4R-tau strain-specific spreading pattern
Metabolic-Support Secretome Dysfunction	0.730	neurodegeneration	Which specific factors in conditioned me
Temporal order is subtype-specific rather than universal	0.730	neurodegeneration	What determines the temporal sequence of
Plasma Claudin-5 Proteolytic Fragments Distinguish Paracellu	0.705	-	What blood-brain barrier permeability ch
Spatiotemporal coupling between TRPML1-mediated lysosomal ca	0.705	neurodegeneration	What determines the specificity of calci
Axonal RNA Transport Reconstitution	0.695	neurodegeneration	RNA binding protein dysregulation across
Temporal Microglial State Switching	0.695	-	Neuroinflammation and microglial priming
SNCA Aggregation Hijacks the Endosomal Sorting Complex Requi	0.690	neurodegeneration	-
Temporal CAG Repeat Stabilization via CRISPR-Mediated DNA Mi	0.681	neurodegeneration	CRISPR-based therapeutic approaches for
NMN Adenosine Transport Enhancement for Cortical Neuron Sene	0.680	neurodegeneration	-
Gamma entrainment corrects AD-related clock gene dysregulati	0.676	alzheimers	Gamma entrainment therapy to restore hip
Mitophagy and NAD pathway enhancement in sporadic Parkinson'	0.670	neurodegeneration	Test
Rab12 may better report chronic lysosomal stress biology tha	0.670	neurodegeneration	Do pathogenic LRRK2 mutations amplify vo
Aquaporin-4 Polarization Enhancement via TREK-1 Channel Modu	0.668	neurodegeneration	Perivascular spaces and glymphatic clear
Axonal Transport Defect: C9orf72 hexanucleotide expansion im	0.660	neurodegeneration	What are the neuron-specific effects of
Temporal TET2-Mediated Hydroxymethylation Cycling	0.657	neurodegeneration	Epigenetic reprogramming in aging neuron
Parvalbumin Interneuron Vulnerability Links Lactate Transpor	0.656	neurodegeneration	What is the molecular mechanism by which
Microglial TBK1 Deficiency Triggers Senescence-Associated Se	0.650	frontotemporal-dementia	-
eIF2α Phosphorylation Imbalance Disrupts Mitochondrial Prote	0.000	als	-

Mentioning Analyses (0)

Scientific analyses that reference this entity

No analyses mention this entity

Experiments (12)

Experimental studies targeting or related to this entity

Experiment	Type	Disease	Score	Feasibility	Model	Status	Est. Cost
CSF Dynamic Biomarkers for Differential Diagnosis of NPH vs AD with Co	clinical	Alzheimer's Disease	0.900	0.50	aortic endothelial cells	proposed	$6,550,000
SPP1 upregulation in perivascular cells in AD mouse models	exploratory	Alzheimer's disease	0.900	0.00	AD mouse models	proposed	N/A
Spp1 knockout prevents synaptic loss in AD mouse models	validation	Alzheimer's disease	0.900	0.00	Spp1 knockout AD mouse models	proposed	N/A
Single-cell RNA sequencing of microglial states in AD hippocampus	exploratory	Alzheimer's disease	0.850	0.00	AD mouse hippocampus	proposed	N/A
Cell-cell interaction analysis of perivascular-microglial crosstalk	exploratory	Alzheimer's disease	0.800	0.00	AD mouse models	proposed	N/A
Proposed experiment from debate on Perivascular spaces and glymphatic	falsification	Neurodegeneration	0.400	0.50	mouse	proposed	$240,000
s:** - Test tau spreading in AQP4 knockout vs wild-type mice with PSP/	falsification	Neurodegeneration	0.400	0.50	mouse	proposed	$260,000
Proposed experiment from debate on Perivascular spaces and glymphatic	falsification	Neurodegeneration	0.400	0.50	cell_line	proposed	$100,000
Glymphatic-Circadian Axis Enhancement Therapy for Parkinson's Disease	clinical	Parkinson's Disease	0.400	0.50	human	proposed	$5,460,000
CSF Dynamic Biomarkers for Differential Diagnosis of NPH vs AD with Co	clinical	Alzheimer's Disease	0.400	0.50	human	proposed	$5,460,000
NPH Glymphatic System Interaction Experiment	clinical	Neurodegeneration	0.400	0.50	human	proposed	$5,460,000
Vascular Contributions to Alzheimer Disease and Mixed Pathology	clinical	Alzheimer's Disease	0.400	0.50	human	proposed	$5,460,000

Related Papers (20)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year	Citations
Aquaporin-4 in glymphatic system, and its implication for central nervous system [PMID:36796590]	Peng S, Liu J, Liang C, Yang L, Wang G	Neurobiol Dis	2023	2
Uncommon inflammatory/immune-related myelopathies. [PMID:34715593]	Valencia-Sanchez C, Flanagan EP	J Neuroimmunol	2021	2
Glymphatic System Impairment in Alzheimer's Disease and Idiopathic Normal Pressu [PMID:31959516]	Reeves BC, Karimy JK, Kundishora AJ, Mes	Trends Mol Med	2020	1
Inebilizumab-cdon. [PMID:32936251]	Unknown	American journal of health-sys	2020	1
The glymphatic pathway in neurological disorders. [PMID:30353860]	Rasmussen MK, Mestre H, Nedergaard M	Lancet Neurol	2018	1
β-Hydroxybutyrate improves glymphatic system function and alleviates cerebral ed [PMID:41535708]	Yu MJ, Xiong RQ, Wu JW, Li YC, Xie JX et	Acta Pharmacol Sin	2026	0
Neutrophil-microglia interaction drives motor dysfunction in a neuromyelitis opt [PMID:41665955]	Qi F, Lennon VA, Zhao S, Guo Y, Ding H e	J Clin Invest	2026	0
Safety and efficacy of ravulizumab in patients with NMOSD previously treated wit [PMID:41782198]	Bennett JL, Bhattacharyya S, Zabeti A, L	Mult Scler	2026	0
Therapeutic updates in NMOSD and MOGAD: From present practice to future promise. [PMID:41927387]	Elosua-Bayés I, Cobo-Calvo A	Rev Neurol (Paris)	2026	0
Multimodal MR Imaging Reveals the Mechanisms of Post-Cardiac-Arrest Brain edema: [PMID:41933462]	Tan Y, Ye H, Ge Q, Wang P, Liu Z et al.	J Magn Reson Imaging	2026	0
Recurrent aquaporin 4-immunoglobulin G-positive neuromyelitis optica spectrum di [PMID:41915816]	Jiang X, Chen J, Wen Y, Yuan L, Zhang J	The Journal of international m	2026	0
Astragaloside IV alleviates post-traumatic cytotoxic edema via inhibition of AQP [PMID:41916121]	Shen W, Jiang C, Liu X, Wang D, Li G, Hu	Phytomedicine : international	2026	0
Glymphatic System Dysfunction in Central Nervous System Diseases. [PMID:41792880]	Zahran A, Abu-Khazneh O, Bdair M, Hajjeh	CNS neuroscience & therapeutic	2026	0
The postnatal expression of transcripts and proteins in the corpus callosum, as [PMID:41915271]	Mayo F, González-Vinceiro L, Hiraldo-Gon	Journal of physiology and bioc	2026	0
Diagnostic Value of the Kappa Free Light Chain Index to Distinguish MOGAD, NMOSD [PMID:41921124]	Tournier A, Gavoille A, Pique J, Levraut	Neurology	2026	0
Mapping the Brain's Glymphatic System. [PMID:41751308]	Voumvourakis K, Thomaidis NS, Tsiodras S	Biomedicines	2026	0
Novel B-Cell targeting therapy with subcutaneous of atumumab in AQP4-IgG-seroneg [PMID:41909718]	Cao X, Qin D, Wang B, Wang C, Guo S	Frontiers in immunology	2026	0
Physical exercise as a non-pharmacological strategy to enhance glymphatic functi [PMID:41676384]	Ghayourvahdat A, Azimizonuzi H, Ahmed M	IBRO neuroscience reports	2026	0
Enhancing TREM2 expression activates microglia and modestly mitigates tau pathol [PMID:40122810]	["Chen Kai", "Li Fuyao", "Zhang Shuwen",	Journal of neuroinflammation	2025	0
Enhancing TREM2 expression activates microglia and modestly mitigates tau pathol [PMID:40122810]	["Chen Kai", "Li Fuyao", "Zhang Shuwen",	Journal of neuroinflammation	2025	0

Debates (0)

Multi-agent debates referencing this entity

No debates reference this entity

Related Research

Hypotheses and analyses mentioning POR in their description or question text

Selective LXRβ agonists restore ABCA1/ABCG1 expression and APOE lipidation in AP

Score: 0.763 · neuroscience · 2026-04-22

**Molecular Mechanism and Rationale** The molecular basis for selective liver X receptor beta (LXRβ/NR1H2) agonism in A

N-acetylcysteine (NAC) / System Xc⁻ - Mediated GSH Support for Neurovascular Uni

Score: 0.760 · neurodegeneration · 2026-04-25

NAC serves as a GSH precursor and direct antioxidant to inhibit ferroptosis in cerebral microvascular endothelial cells

APOE4 astrocytes exhibit impaired cholesterol efflux via ABCA1/ABCG1 transporter

Score: 0.758 · neuroscience · 2026-04-22

## Mechanistic Overview APOE4 astrocytes exhibit impaired cholesterol efflux via ABCA1/ABCG1 transporters, driving intra

Temporal SPP1 Inhibition During Critical Windows

Score: 0.752 · neuroinflammation · 2026-04-15

## Mechanistic Overview Temporal SPP1 Inhibition During Critical Windows starts from the claim that modulating SPP1 with

APOE4-driven lysosome-to-ER cholesterol transport failure reduces ER-accessible

Score: 0.741 · molecular-biology · 2026-04-24

The strongest synthesis is an indirect mechanism in glia: APOE4 promotes cholesterol sequestration in late endosome/lyso

C9orf72 Hexanucleotide Repeat Dipeptide Repeat Proteins Inhibit Nucleocytoplasmi

Score: 0.738 · neurodegeneration · 2026-04-26

C9orf72 repeat transcripts undergo non-ATG translation producing DPRs (poly-GA, poly-GR, poly-PR) that sequester nucleoc

Aquaporin-4 Polarization Rescue

Score: 0.732 · neurodegeneration · 2026-04-02

## Mechanistic Overview Aquaporin-4 Polarization Rescue starts from the claim that modulating AQP4 within the disease co

Metabolic-Support Secretome Dysfunction

Score: 0.730 · neurodegeneration · 2026-04-25

Healthy astrocytes provide a balanced fuel/redox/pH composition (including lactate, glucose, pyruvate, and NAD+/NADH-rel

Temporal order is subtype-specific rather than universal

Score: 0.730 · neurodegeneration · 2026-04-25

The most defensible synthesis is that AD contains at least two trajectory classes: an amyloid-clearance/endosomal class

Plasma Claudin-5 Proteolytic Fragments Distinguish Paracellular BBB Breakdown fr

Score: 0.705 · unknown disease · 2026-04-26

Claudin-5 is the most abundant tight junction protein in brain endothelial cells and is specifically degraded during ear

Spatiotemporal coupling between TRPML1-mediated lysosomal calcium release and ca

Score: 0.705 · neurodegeneration · 2026-04-21

**Molecular Mechanism and Rationale** The spatiotemporal coupling between TRPML1-mediated lysosomal calcium release and

Axonal RNA Transport Reconstitution

Score: 0.695 · neurodegeneration · 2026-04-02

## Mechanistic Overview Axonal RNA Transport Reconstitution starts from the claim that modulating HNRNPA2B1 within the d

Temporal Microglial State Switching

Score: 0.695 · unknown disease · 2026-04-04

## Mechanistic Overview Temporal Microglial State Switching starts from the claim that modulating Optogenetic constructs

Temporal CAG Repeat Stabilization via CRISPR-Mediated DNA Mismatch Repair Modula

Score: 0.681 · neurodegeneration · 2026-04-04

## Mechanistic Overview Temporal CAG Repeat Stabilization via CRISPR-Mediated DNA Mismatch Repair Modulation starts from